Biopharmaceutical News and Research

RSS

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.

21 Jun 2014

Researchers develop tissue engineered bone grafts for healing large bone defects

Bone is one of the most frequently transplanted tissues. And the demand is rising. Transplants treat large defects like those caused by trauma, complicated fractures, tumour resection or osteoporosis.

20 Jun 2014

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

19 Jun 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.

16 Jun 2014

Auxilium and Prasco introduce authorized generic version of Testim

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel).

11 Jun 2014

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients.

11 Jun 2014

Protein Metrics introduces top-down analysis as part of 2.0 release of Byonic proteomics search engine

Protein Metrics, Inc., a leading provider of software for rapid and thorough protein and peptide characterization, today announced the introduction of top-down analysis as part of the 2.0 release of its Byonic™ proteomics search engine.

11 Jun 2014

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

Auxogyn receives clearance from FDA for Eeva System

Auxogyn, Inc. a leader in women's reproductive health, today announced that its first product, the Eeva System, received clearance from the U.S. Food and Drug Administration through its de novo classification process, a regulatory pathway for select novel, low- to moderate-risk medical devices that are first-of-a-kind.

10 Jun 2014

$arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM$

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

REM sleep disorder: A sign of impending neurodegenerative disease

How many millions of people suffer from sleep disturbance? One sleep disorder in particular, called REM behavior disorder, could be a sign of impending neurodegenerative disease, including Parkinson's and dementia, say scientists presenting their research at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

10 Jun 2014

Merck enters into definitive agreement with Idenix

Merck, known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc., today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash.

9 Jun 2014

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.

9 Jun 2014

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

9 Jun 2014

Advances in understanding of genetics of CAD lead to more therapeutic targets

Advances in the understanding of the genetics of coronary artery disease, or CAD, will revitalize the field and lead to more therapeutic targets for new medicines to combat this common disease, suggests a genetics expert from the Perelman School of Medicine at the University of Pennsylvania in a Perspective article in the new issue of Science Translational Medicine.

9 Jun 2014

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.

6 Jun 2014

$SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus$

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).

5 Jun 2014

arGEN-X, Shire Pharmaceuticals announce long-term strategic alliance in therapeutic antibodies

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals.

4 Jun 2014

Biopharmaceutical News and Research

Celsion acquires all assets of EGEN

Researchers develop tissue engineered bone grafts for healing large bone defects

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Arrowhead Research joins with broad-market Russell 3000 Index

Auxilium and Prasco introduce authorized generic version of Testim

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

Protein Metrics introduces top-down analysis as part of 2.0 release of Byonic proteomics search engine

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Auxogyn receives clearance from FDA for Eeva System

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

Celsion signs definitive asset purchase agreement to acquire EGEN

REM sleep disorder: A sign of impending neurodegenerative disease

Merck enters into definitive agreement with Idenix

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Advances in understanding of genetics of CAD lead to more therapeutic targets

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

arGEN-X, Shire Pharmaceuticals announce long-term strategic alliance in therapeutic antibodies

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News